These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 28779652)
1. Varying the metal to ethacrynic acid ratio in ruthenium(ii)/osmium(ii)-p-cymene conjugates. Păunescu E; Soudani M; Clavel CM; Dyson PJ J Inorg Biochem; 2017 Oct; 175():198-207. PubMed ID: 28779652 [TBL] [Abstract][Full Text] [Related]
2. Highly Cytotoxic Osmium(II) Compounds and Their Ruthenium(II) Analogues Targeting Ovarian Carcinoma Cell Lines and Evading Cisplatin Resistance Mechanisms. Hildebrandt J; Häfner N; Kritsch D; Görls H; Dürst M; Runnebaum IB; Weigand W Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563367 [TBL] [Abstract][Full Text] [Related]
3. Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs. Ang WH; De Luca A; Chapuis-Bernasconi C; Juillerat-Jeanneret L; Lo Bello M; Dyson PJ ChemMedChem; 2007 Dec; 2(12):1799-806. PubMed ID: 17918761 [TBL] [Abstract][Full Text] [Related]
4. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions. Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150 [TBL] [Abstract][Full Text] [Related]
5. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity. Peacock AF; Parsons S; Sadler PJ J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668 [TBL] [Abstract][Full Text] [Related]
7. Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates. Riedl CA; Flocke LS; Hejl M; Roller A; Klose MH; Jakupec MA; Kandioller W; Keppler BK Inorg Chem; 2017 Jan; 56(1):528-541. PubMed ID: 27996251 [TBL] [Abstract][Full Text] [Related]
9. Short divalent ethacrynic amides as pro-inhibitors of glutathione Xu B; Tong T; Wang X; Liu F; Zhang X; Hu X; Li X; Yang X; Liao F J Enzyme Inhib Med Chem; 2022 Dec; 37(1):728-742. PubMed ID: 35176963 [TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic and Anticancer Properties of Bifunctional Ruthenium(II)-p-Cymene Complexes: Influence of Pendant Perfluorous Chains. Nowak-Sliwinska P; Clavel CM; Păunescu E; te Winkel MT; Griffioen AW; Dyson PJ Mol Pharm; 2015 Aug; 12(8):3089-96. PubMed ID: 26158308 [TBL] [Abstract][Full Text] [Related]
11. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes. van Rijt SH; Hebden AJ; Amaresekera T; Deeth RJ; Clarkson GJ; Parsons S; McGowan PC; Sadler PJ J Med Chem; 2009 Dec; 52(23):7753-64. PubMed ID: 19791745 [TBL] [Abstract][Full Text] [Related]
16. Conjugation of a Ru(II) arene complex to neomycin or to guanidinoneomycin leads to compounds with differential cytotoxicities and accumulation between cancer and normal cells. Grau-Campistany A; Massaguer A; Carrion-Salip D; Barragán F; Artigas G; López-Senín P; Moreno V; Marchán V Mol Pharm; 2013 May; 10(5):1964-76. PubMed ID: 23510087 [TBL] [Abstract][Full Text] [Related]
17. Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug. Lee KGZ; Babak MV; Weiss A; Dyson PJ; Nowak-Sliwinska P; Montagner D; Ang WH ChemMedChem; 2018 Jun; 13(12):1210-1217. PubMed ID: 29637702 [TBL] [Abstract][Full Text] [Related]